Overview

Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.

Status:
Withdrawn

Trial end date:
2006-02-02

Target enrollment:

Participant gender:

Summary

We hypothesize use of the insulin pump will improve body weight, lean body mass, whole body protein turnover, hepatic glucose production (HGP), and blood sugar control in CF patients with impaired glucose tolerance or patients with CF related diabetes (CFRD). We further hypothesize that HGP is also elevated in children/adolescents with type 1 diabetes and that the insulin pump will result in decreased HGP.

Phase:

N/A

Details

Lead Sponsor:

University of Texas Southwestern Medical Center

Treatments:

Insulin
Insulin, Globin Zinc